Edition:
United States

TapImmune Inc (TPIV.OQ)

TPIV.OQ on NASDAQ Stock Exchange Capital Market

3.09USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.09
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,651
52-wk High
$5.35
52-wk Low
$2.62

Chart for

About

TapImmune Inc. is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The Company is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers.... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): --
Shares Outstanding(Mil.): 10.54
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Tapimmune Q3 loss earnings per share $0.39‍​

* Tapimmune provides third quarter 2017 corporate and clinical update

Nov 15 2017

BRIEF-TapImmune appoints Peter Hoang as president and CEO

* TapImmune appoints Peter Hoang as president and chief executive officer

Sep 25 2017

BRIEF-Tapimmune files for‍​ resale of 4.4 mln shares of common stock held by selling stockholders

* Tapimmune Inc - Files for‍​ resale 4.4 million shares of common stock which are currently held by selling stockholders - SEC filing Source text: [http://bit.ly/2hjwILz] Further company coverage:

Sep 20 2017

BRIEF-TapImmune reaches 50 pct patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer

* TapImmune reaches 50% patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer

Jun 27 2017

BRIEF-TapImmune to raise $6.82 million in a private placement

* Tapimmune inc. Enters into definitive agreements to raise $6.82 million in a private placement from accredited investors and from the exercise of warrants by existing institutional investors

Jun 22 2017

Earnings vs. Estimates

No consensus analysis data available.